News

Public · Published

Radiopharm Theranostics and FDA Agree on Design of Phase 3 RAD101 Trial for Brain Metastases

Radiopharm Theranostics agreed with the US Food and Drug Administration on the design of a pivotal Phase 3 trial of RAD101, an imaging agent for patients with uncertain brain metastases after radiotherapy. The company expects to enrol 280 patients and measure the agent's sensitivity and specificity against a reference standard.

Published:

Updated:

What happened

Radiopharm Theranostics agreed with the US Food and Drug Administration on the design of a pivotal Phase 3 trial of RAD101, an imaging agent for patients with uncertain brain metastases after radiotherapy. The company expects to enrol 280 patients and measure the agent’s sensitivity and specificity against a reference standard.

Confirmed

Global impact / market context

Agreement on the trial design may reduce uncertainty about the evidence regulators expect, helping Radiopharm advance RAD101 toward a possible approval decision. If the trial succeeds and the agent is adopted, revenue could follow, while trial spending and development costs will come first.

Analyst inference

This remains a clinical-development story, not a confirmed commercial launch: RAD101 must still be evaluated in the planned Phase 3 trial. The article gives no trial timing, results, cost, funding details, or approval outlook, so near-term value depends on execution and evidence.

Analyst inference

What to watch

  1. Watch for enrolment progress toward the planned 280 patients and whether the trial reports results for both sensitivity and specificity against its stated reference standard. Analyst inference
  2. Look for any announced trial start, completion timing, or spending details, which would clarify how long Radiopharm must fund development before results become available. Analyst inference
  3. Check whether later company updates describe RAD101’s performance in distinguishing recurrent cancer from treatment effects, the clinical problem identified in the article. Analyst inference

Evidence